Home Cart Sign in  
Chemical Structure| 49562-28-9 Chemical Structure| 49562-28-9

Structure of Fenofibrate
CAS No.: 49562-28-9

Chemical Structure| 49562-28-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fenofibrate is an agonist of PPARα (EC50 = 30 μM) and an inhibitor of CYP2C19 (IC50 = 0.2 μM) and CYP2B6 (IC50 = 0.7 μM). Fenofibrate is a fibric acid derivative and used to treat hypercholesterolemia and hypertriglyceridemia.

Synonyms: NSC-281319

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fenofibrate

CAS No. :49562-28-9
Formula : C20H21ClO4
M.W : 360.83
SMILES Code : CC(C)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C(OC(C)C)=O
Synonyms :
NSC-281319
MDL No. :MFCD00133314
InChI Key :YMTINGFKWWXKFG-UHFFFAOYSA-N
Pubchem ID :3339

Safety of Fenofibrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T cells 5 µM 12 hours To evaluate the ability of fenofibrate to activate CB1 through the Gq signaling pathway, results showed that fenofibrate significantly increased calcium-induced luciferase activity Adv Sci (Weinh). 2024 Apr;11(14):e2306311.
HEK293F cells 50 µM 2 hours Used for the expression and purification of CB1 protein, fenofibrate was used to stabilize the CB1-Gq complex Adv Sci (Weinh). 2024 Apr;11(14):e2306311.
LN18 cells 50 µM 24 hours Radioprotects LN18 cells by reducing the production of reactive oxygen species (ROS) and stabilizing the mitochondrial membrane potential Redox Biol. 2025 Feb;79:103452.
U87 cells 50 µM 24 hours Significantly radiosensitizes U87 cells by inducing DNA double-strand breaks through oxidative stress and impairing mitochondrial membrane integrity Redox Biol. 2025 Feb;79:103452.
HL-1 cells 100 µM 24 hours Fenofibrate inhibits atrial metabolic remodeling through PPAR-α/sirtuin 1/PGC-1α pathway Br J Pharmacol. 2016 Mar;173(6):1095-109.
Human kidney proximal tubular epithelial cells (HK2 cells) 50 µM 24 hours Fenofibrate reduced lipid accumulation and ameliorated apoptosis in HK2 cells by activating the AMPK/FOXA2/MCAD signaling pathway Drug Des Devel Ther. 2023 May 18;17:1503-1514.
ARPE-19 cells 10, 20, 50 µM 24 hours To investigate the effect of fenofibric acid on PA-induced ARPE-19 cell injury. Results showed that fenofibric acid significantly inhibited PA-induced oxidative stress and inflammatory response, and promoted cell proliferation. Drug Des Devel Ther. 2023 Nov 21;17:3439-3452.
CD4+ T cells 2 µM 3 days To investigate the effect of Fenofibrate on Th1, Th17, and Treg cell differentiation; results showed that Fenofibrate decreased the frequencies of Th1 and Th17 cells and increased the proportion of Treg cells Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):12.
H9c2 cells 10 µM, 50 µM, 100 µM 3 days To investigate the protective effect of fenofibrate on high glucose and palmitate-induced apoptosis in H9c2 cells. Results showed that fenofibrate pretreatment significantly reduced cell death induced by high glucose plus palmitate, decreased the proportion of apoptotic and necrotic cells, and reduced intracellular lipid accumulation. Cardiovasc Diabetol. 2024 Sep 16;23(1):343.
Peripheral blood mononuclear cells (PBMC) 100 µM 48 hours To evaluate the effect of fenofibrate on the expression of pro-inflammatory mediators in PBMC. Results showed that fenofibrate significantly reduced the expression levels of IL-12, TGF-β, IL-6, and MCP-1. Front Cell Infect Microbiol. 2022 Mar 11;11:785166.
HepG2 cells 100 µM To verify the activation effect of Fenofibrate on PPARα and its impact on the expression of lipid metabolism-related genes Elife. 2021 Dec 29;10:e70472.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD mice Sjögren syndrome-like dry eye model Oral 0.03% 8 weeks To evaluate the therapeutic effect of Fenofibrate on autoimmune dacryoadenitis; results showed that Fenofibrate significantly reduced lymphocytic infiltration in lacrimal glands, increased tear secretion, decreased corneal fluorescein staining scores, and modulated Th1/Th17/Treg cell responses Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):12.
NOD mice Sjögren syndrome-like dry eye model Fed chow 0.03% 8 weeks To evaluate the therapeutic effect of Fenofibrate on autoimmune dacryoadenitis; results showed that Fenofibrate significantly reduced lymphocytic infiltration in lacrimal glands, increased tear secretion, decreased corneal fluorescein staining scores, and modulated Th1/Th17/Treg cell responses Invest Ophthalmol Vis Sci. 2022 Jun 1;63(6):12.
C57BL/6J mice Obese female ovariectomized mice Dietary supplementation 0.05% (w/w) 21 weeks Fenofibrate inhibits visceral obesity and nonalcoholic fatty liver disease through visceral adipose tissue PPARα activation in obese female OVX mice Int J Mol Sci. 2021 Apr 1;22(7):3675
C57BL/6J mice High-fat diet (HFD)-fed ovariectomized (OVX) mice Dietary supplementation 0.05% (w/w) For 9 weeks To investigate the effects of fenofibrate on insulin resistance and tissue inflammation in HFD-fed OVX mice. Results showed that fenofibrate reduced body weight gain, adipose tissue mass, and visceral adipocyte size, improved mild hyperglycemia, severe hyperinsulinemia, and glucose tolerance, and decreased CD68-positive macrophages in both the pancreas and visceral adipose tissue. Nutr Diabetes. 2023 Nov 7;13(1):19
C57BL/6J mice High-fat diet-induced retinal pigment epithelium injury model Dietary supplementation 0.1% (w/w) Once daily for 1 month To investigate the protective effect of fenofibrate on high-fat diet-induced retinal pigment epithelium injury. Results showed that fenofibrate significantly improved retinal function and inhibited oxidative stress and inflammatory response. Drug Des Devel Ther. 2023 Nov 21;17:3439-3452.
Rats Young and old rats Mixed into chow 0.1% and 0.5% (w/w) Daily for 30 days To investigate the effects of fenofibrate on kidney structure and molecular effectors in young and old rats. Results showed that high-dose fenofibrate activated multiple stress pathways in the aged kidney, while low-dose fenofibrate more prominently induced fatty acid oxidation genes in old rats. Int J Mol Sci. 2024 Mar 6;25(5):3038
C57BL/6J male mice High-fat diet (HFD)-induced mice model Oral 0.1% w/w Once daily for 1 month To investigate the ameliorative effects of fenofibrate on systemic and retinal inflammation, as well as gut microbiota dysbiosis in high-fat diet (HFD)-induced mice. Results showed that fenofibrate significantly alleviated HFD-induced body weight gain, dyslipidemia, intestinal barrier dysfunction, systemic and retinal inflammation, and modulated gut microbiota composition. Front Cell Infect Microbiol. 2022 Jun 2;12:839592
Mice NSCLC model Dietary administration 0.2% (wt/wt) Starting at 6.5 weeks and continued Restoring hepatic ketogenesis and preventing skeletal muscle loss Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E743-E752
Mice NAFLD model induced by high-fat diet (HFD) or methionine-deficient diet (MCD) Oral 100 mg/kg 4 weeks To evaluate the therapeutic effect of Fenofibrate on NAFLD mouse model, it was found that overexpression of Mir20b suppressed the efficacy of Fenofibrate Elife. 2021 Dec 29;10:e70472.
Mice Db/db mice and high fat diet-streptozotocin induced diabetic mice Oral 100 mg/kg/day Once daily for 8 weeks To investigate the protective effects of fenofibrate on obesity- and diabetes-related cardiomyopathy. Results showed that fenofibrate treatment significantly improved cardiac function, reduced left ventricular mass, enhanced left ventricular ejection fraction, and decreased cardiac fibrosis and lipid accumulation. Additionally, fenofibrate reduced total cholesterol and triglyceride levels and increased HDL cholesterol levels in the blood. Cardiovasc Diabetol. 2024 Sep 16;23(1):343.
Female NOD mice NOD mice Diet 00.1% From 3 weeks of age until the experiment was terminated To investigate the effects of fenofibrate on the pancreatic lipidome, pancreas morphology, pancreatic sympathetic nerves and blood glucose homeostasis in NOD mice. Results showed that fenofibrate selectively increases the amount of very-long-chain sphingolipids in the pancreas of NOD mice and causes a remodeling of the pancreatic lipidome with an increased amount of lysoglycerophospholipids. Fenofibrate did not affect islet or pancreas volume but led to a higher volume of islet sympathetic nerve fibers and tyrosine hydroxylase-positive cells. Fenofibrate-treated NOD mice had a more stable blood glucose, which was associated with reduced non-fasting and increased fasting blood glucose. Furthermore, fenofibrate improved glucose tolerance, reduced fasting glucagon levels, and prevented fasting hyperinsulinemia. Diabetologia. 2019 Dec;62(12):2262-2272
Db/db mice Type 2 diabetes and diabetic kidney disease model Intragastric gavage 100 mg/kg/day Once daily for 8 weeks Fenofibrate improved renal function and alleviated renal pathological damage by activating the AMPK/FOXA2/MCAD signaling pathway, reducing lipid accumulation and apoptosis Drug Des Devel Ther. 2023 May 18;17:1503-1514.
New Zealand white rabbits Atrial fibrillation model Oral 125 mg/kg/day Once daily for 14 days Fenofibrate inhibits atrial metabolic remodeling by regulating the PPAR-α/sirtuin 1/PGC-1α pathway Br J Pharmacol. 2016 Mar;173(6):1095-109.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00673881 Dyslipidemia Phase 1 Phase 2 Completed - United States, Illinois ... More >> Radiant Research, 515 N State St, #2700 Chicago, Illinois, United States, 60610 Less <<
NCT00261352 Type 2 Diabetes Phase 3 Terminated(The development pro... More >>gram has been terminated) Less << - -
NCT00195793 Hyperlipidemia Phase 3 Completed - -
NCT00361868 Dyslipidemia ... More >>Glucose Metabolism Disorder Less << Phase 3 Terminated(The study was disco... More >>ntinued prematurely at the end of March 2007 due to slow enrolment.) Less << - -
NCT00504829 Dyslipidemia Phase 2 Completed - United States, Illinois ... More >> Radiant Research, 515 N State Street, Suite 2700 Chicago, Illinois, United States, 60610 Less <<
NCT00754039 Hypercholesterolemia ... More >> Hyperlipidemia, Familial Combined Less << Phase 4 Completed - United States, Florida ... More >> Longwood, Florida, United States Ocala, Florida, United States Winterpark, Florida, United States United States, Illinois Chicago, Illinois, United States Lombard, Illinois, United States United States, Kansas Overland Park, Kansas, United States United States, North Carolina Stateville, North Carolina, United States United States, Ohio Cincinnati, Ohio, United States United States, Texas San Antonio, Texas, United States United States, Virginia Richmond, Virginia, United States Less <<
NCT00385658 Dyslipidemia Phase 4 Completed - Germany ... More >> Investigative Centers, Germany Switzerland Novartis Pharma AG Basel, Switzerland Less <<
NCT01767610 Healthy Male Volunteers Phase 1 Completed - Korea, Republic of ... More >> Kyungpook National University Hospital Daegu, Korea, Republic of, 700-721 Less <<
NCT00362323 Dyslipidemia/Glucose Metabolis... More >>m Disorder Less << Phase 3 Completed - -
NCT00076518 HIV Infections ... More >> Hypertriglyceridemia Less << Phase 2 Completed - United States, California ... More >> Ucsf Aids Crs San Francisco, California, United States, 94110 United States, Georgia The Ponce de Leon Ctr. CRS Atlanta, Georgia, United States, 30308 United States, Ohio Univ. of Cincinnati CRS Cincinnati, Ohio, United States, 45267-0405 Case CRS Cleveland, Ohio, United States, 44106-5083 United States, Rhode Island The Miriam Hosp. ACTG CRS Providence, Rhode Island, United States, 02906 Less <<
NCT02158273 Alcoholism Phase 2 Completed - United States, California ... More >> Susan Quello La Jolla, California, United States, 92037 Less <<
NCT02158273 - Completed - -
NCT00349635 Obesity Phase 2 Completed - Finland ... More >> Site 1 Helsinki, Finland Site 3 Kuopio, Finland Site 2 Oulu, Finland Less <<
NCT00362765 Type 2 Diabetes ... More >> Dyslipidemia Less << Phase 2 Phase 3 Terminated(The study was prema... More >>turely terminated, due to difficulties in the recruitment of T2DM patients who are not under statin therapy at inclusion.) Less << - Finland ... More >> Site 2 Turku, Finland Ireland Site 3 Dublin, Ireland Italy Site 1 Pisa, Italy Less <<
NCT02066207 Dyslipidemia (Fredrickson Type... More >> Ⅱa) Dyslipidemia (Fredrickson Type Ⅱb) Less << Phase 1 Completed - Korea, Republic of ... More >> Samsung Medical Center Seoul, Korea, Republic of Less <<
NCT00470262 Metabolic Syndrome X ... More >> Prediabetic State Less << Not Applicable Completed - United States, Colorado ... More >> VA Eastern Colorado Health Care System, Denver Denver, Colorado, United States, 80220 Less <<
NCT00376285 Obesity Phase 1 Withdrawn - -
NCT00683176 Diabetic Macular Edema Phase 2 Completed - Bulgaria ... More >> Site Reference ID/Investigator# 54268 Sofia, Bulgaria, 1000 Site Reference ID/Investigator# 54291 Sofia, Bulgaria, 1233 Site Reference ID/Investigator# 54279 Sofia, Bulgaria, 1408 Site Reference ID/Investigator# 54273 Sofia, Bulgaria, 1517 Czech Republic Site Reference ID/Investigator# 54267 Brno, Czech Republic, 62500 Site Reference ID/Investigator# 54282 Ostrava-Vitkovice, Czech Republic, 703 84 Site Reference ID/Investigator# 54283 Prague, Czech Republic, 169 02 Site Reference ID/Investigator# 54270 Usti nad Labem, Czech Republic, 40113 Denmark Site Reference ID/Investigator# 54274 Glostrup, Denmark, 2600 Germany Site Reference ID/Investigator# 54263 Leipzig, Germany, 04103 Site Reference ID/Investigator# 54284 Muenster, Germany, 48145 Hungary Site Reference ID/Investigator# 54269 Budapest, Hungary, 1106 Site Reference ID/Investigator# 54277 Gyor, Hungary, H-9023 Site Reference ID/Investigator# 54275 Zalaegerszeg - Pozva, Hungary, 8900 Italy Site Reference ID/Investigator# 54272 Udine, Italy, 33100 Netherlands Site Reference ID/Investigator# 54293 Amsterdam, Netherlands, 1105 AZ Poland Site Reference ID/Investigator# 54265 Gdansk, Poland, 80-147 Site Reference ID/Investigator# 54266 Katowice, Poland, 40-760 Spain Site Reference ID/Investigator# 54280 Madrid, Spain, 28002 Site Reference ID/Investigator# 54264 Santiago de Compostela, Spain, 15705 United Kingdom Site Reference ID/Investigator# 54271 Liverpool, United Kingdom, L7 8XP Less <<
NCT00923676 Sexual Dysfunction ... More >> Hyperlipidemia Less << Phase 4 Unknown April 2016 Italy ... More >> Department of Geriatrics and Metabolic Diseases Naples, Italy, 80138 Less <<
NCT00470262 - Completed - -
NCT01666041 Hypertriglyceridemia Phase 4 Completed - Korea, Republic of ... More >> Gil Medical Center Incheon, Korea, Republic of, 405-760 Less <<
NCT00348725 Dyslipidemia/Glucose Metabolis... More >>m Disorder Less << Phase 3 Completed - France ... More >> Site 24 Anzin, France Site 23 Bachant, France Site 21 Baune, France Site 32 Bersee, France Site 34 Briollay, France Site 27 Denain, France Site 28 Denain, France Site 5 Le Temple de Bretagne, France Site 29 Nantes, France Site 2 Nantes, France Site 8 Nantes, France Site 9 Nantes, France Site 1 Nort sur Erdre, France Site 13 Parcay les Pins, France Site 26 Quarouble, France Site 7 Saint Aignan le Grand, France Site 4 Saint Herblain, France Site 30 Saint-Amand, France Site 11 Sautron, France Site 17 Segre, France Site 10 St Etienne de Montluc, France Site 33 Thiant, France Site 12 Thouars, France Site 25 Vieux Conde, France Site 20 Vihiers, France Less <<
NCT00349128 Dyslipidemia/Glucose Metabolis... More >>m Disorder Less << Phase 2 Phase 3 Completed - -
NCT00006412 HIV Infections ... More >> Lipodystrophy Less << Phase 3 Completed - -
NCT00186537 Insulin Resistance ... More >> Hypertriglyceridemia Less << Not Applicable Completed - United States, California ... More >> Stanford University Medical Center Stanford, California, United States, 94305 Less <<
NCT01674712 - Completed - -
NCT00745407 Hypertriglyceridemia Phase 4 Completed - Korea, Republic of ... More >> Gil Medical Center Incheon, Korea, Republic of, 405760 Less <<
NCT00543647 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> Site 1 London, United Kingdom Less <<
NCT01674712 Dyslipidemia Phase 3 Completed - -
NCT02250976 Healthy Male Volunteers Phase 1 Completed - Korea, Republic of ... More >> Kyungpook National University Hospital Daegu, Korea, Republic of, 700-721 Less <<
NCT01539616 Hypertriglyceridemia ... More >> Dyslipidemia Less << Phase 2 Completed - India ... More >> Vijayratna Diabetes Diagnosis & Treatment Centre, Upper Ground Floor, Sumeru Centre, Nr Parimal Underbridge, Paldi Ahmedabad, Gujarat, India, 380007 Devi Hospital,Ground floor, Naranpura Ahmedabad, Gujarat, India, 380008 Private clinic, 4, Stadium House, Ground Floor, Navrangpura Ahmedabad, Gujarat, India, 380009 Dia Care Reseach, 1&2- Gandhi Park Society, Nr. Nehrunagar Cross Roads, Ambawadi Ahmedabad, Gujarat, India, 380015 Govt. Medical College, Bhavnagar Bhavnagar, Gujarat, India, 364001 Gastrocare Clinic,Ground floor, Karansinhji Main Road, Rajkot, Gujarat, India, 360001 Balaji Hospital,First floor,clinical research department, Opp. Vidya Vikas School, Subhanpura, Vadodara, Gujarat, India, 390 023 Pace Clinical Research (A. Unit of Pranav Diabetes Centre), No. 53, Nanda Complex, Ramamurthy Nagar Main Road, Banasawadi Bangalore, Karnataka, India, 560 043 Srinivasa clinic and Diabetic Care centre, 197, 2nd floor, Near Avalahalli BDA park, BSK 3rd stage Bangalore, Karnataka, India, 560085 Mallige Healthcare Centre, # 402, 8th main, 8th cross, Near Dr. M. C. Modi Compound. P.J.EXTN, Davangere, Karnataka, India, 577002 Deogiri Diabetes Centre, 46 Samata Nagar, Near Kranti Chowk Police Station Aurangabad, Maharashtra, India, 431001 Bhatia Hospital, Tardeo Road,Room no 19, Basement floor,Research room, Mumbai, Maharashtra, India, 400007 Pai Clinic & Diagnostic Centre - Abhinav Apartments, 778/B-4, First floor, Shivajinagar, Next to Congress House Pune, Maharashtra, India, 411005 Shree Nidan Hospital, Clinical trial department, First floor, 27-28 Vidhyut nagar-A, Ajmer road Jaipur, Rajasthan, India, 302024 Mother's Care Diabetes Centre, Room no 9, Phase 1, Sathuvachari Vellore, Tamil Nadu, India, 632009 Aruna Diabetes Centre, 56,Thiruvengatapuram, Near Nungambakkam Railway Station, Choolamedu Chennai, Tamilnadu, India, 600094 Department of Endocrinology, Room No.9, 4 th Floor, Ronald Ross Building, Institute of Post Graduate Medical Education & Research, 244 AJC Bose Road. Kolkata, West Bengal, India, 700020 Room no 3027,Research block B,Department of Endocrinology PGIMER Chandigarh, India, 160012 Less <<
NCT03439345 Diabetic Retinopathy Phase 4 Recruiting August 2023 United Kingdom ... More >> NHS Grampian Recruiting Aberdeen, United Kingdom NHS Lanarkshire Recruiting Airdrie, United Kingdom NHS Ayrshire and Arran Recruiting Ayr, United Kingdom NHS Dumfries and Galloway Not yet recruiting Dumfries, United Kingdom NHS Tayside Recruiting Dundee, United Kingdom NHS Fife Recruiting Dunfermline, United Kingdom NHS Lanarkshire Recruiting East Kilbride, United Kingdom NHS Lothian Recruiting Edinburgh, United Kingdom NHS Greater Glasgow and Clyde Recruiting Glasgow, United Kingdom NHS Highland Recruiting Inverness, United Kingdom NHS Ayrshire and Arran Recruiting Kilmarnock, United Kingdom NHS Fife Recruiting Kirkcaldy, United Kingdom NHS Forth Valley Recruiting Larbert, United Kingdom NHS Borders Recruiting Melrose, United Kingdom NHS Tayside Recruiting Perth, United Kingdom NHS Lanarkshire Recruiting Wishaw, United Kingdom Less <<
NCT01003847 Hypertriglyceridemia Phase 4 Completed - Korea, Republic of ... More >> Gil Medical Center Incheon, Korea, Republic of, 405-760 Less <<
NCT01414803 Hyperlipidemia Phase 4 Completed - Korea, Republic of ... More >> Severance Hospital Seoul, Korea, Republic of, 120-752 Less <<
NCT00186537 - Completed - -
NCT00490178 Diabetes Mellitus, Type 2 ... More >> Dyslipidemia Less << Phase 3 Completed - France ... More >> Site 3 Marseille, France Site 1 Nantes, France Site 2 Tours, France Less <<
NCT00139061 Hyperlipidemia Phase 3 Completed - France ... More >> Pfizer Investigational Site Angers, France, 49 000 Pfizer Investigational Site Angers, France, 49 100 Pfizer Investigational Site Bordeaux Cauderan, France, 33 200 Pfizer Investigational Site Briollay, France, 49125 Pfizer Investigational Site Dijon, France, 21000 Pfizer Investigational Site Hagondange, France, 57 300 Pfizer Investigational Site Haut Mauco, France, 40 280 Pfizer Investigational Site Jarny, France, 54800 Pfizer Investigational Site Lille, France, 59 037 Cedex Pfizer Investigational Site Mars LA Tour, France, 54800 Pfizer Investigational Site Metz, France, 57070 Pfizer Investigational Site Monguilhem, France, 32 240 Pfizer Investigational Site Mont de Marsan CEDEX, France, 40010 Pfizer Investigational Site Mont de Marsan, France, 40 010 cedex Pfizer Investigational Site Mont de Marsan, France, 40 010 Pfizer Investigational Site Mont de Marsan, France, 40000 Pfizer Investigational Site Moutiers, France, 54660 Pfizer Investigational Site Murs Erigne, France, 49610 Pfizer Investigational Site Nantes, France, 44 093 Cedex 01 Pfizer Investigational Site Pouilly en Auxois, France, 21 850 Pfizer Investigational Site Saint Justin, France, 40 240 Pfizer Investigational Site Saint Martin D'Oney, France, 40090 Pfizer Investigational Site Seysses, France, 31600 Pfizer Investigational Site Strasbourg, France, 67000 Pfizer Investigational Site Thouars, France, 79100 Pfizer Investigational Site Tierce, France, 49 125 Less <<
NCT01426438 - Completed - -
NCT01723735 Hypercholesterolemia Phase 1 Completed - France ... More >> Investigational Site Number 250001 Rennes, France, 35000 Investigational Site Number 250002 Rueil Malmaison, France, 92502 Less <<
NCT01594983 Non Familial Chylocmicronemia ... More >>Syndrome (Non-FCS) Less << Phase 2 Completed - -
NCT01426438 HIV-1 Infection Phase 2 Completed - United States, Alabama ... More >> Alabama Therapeutics CRS (5801) Birmingham, Alabama, United States, 35294 United States, California University of Southern California (1201) Los Angeles, California, United States, 90033-1079 UCLA CARE Center CRS (601) Los Angeles, California, United States, 90095 Harbor-UCLA Med. Ctr. CRS (603) Torrance, California, United States, 90502 United States, Colorado University of Colorado Hospital CRS (6101) Aurora, Colorado, United States, 80045 United States, Illinois Northwestern University CRS (2701) Chicago, Illinois, United States, 60611 United States, New Jersey New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477) Newark, New Jersey, United States, 07103 United States, New York NY Univ. HIV/AIDS CRS (401) New York, New York, United States, 10016 United States, North Carolina Unc Aids Crs (3201) Chapel Hill, North Carolina, United States, 27516 Duke Univ. Med. Ctr. Adult CRS (1601) Durham, North Carolina, United States, 27710 Moses H. Cone Memorial Hospital CRS (3203) Greensboro, North Carolina, United States, 27401 United States, Ohio Univ. of Cincinnati CRS (2401) Cincinnati, Ohio, United States, 45267 Case CRS (2501) Cleveland, Ohio, United States, 44106 United States, Washington University of Washington AIDS CRS (1401) Seattle, Washington, United States, 98104 Less <<
NCT00422396 Hypertriglyceridemia With the ... More >>Metabolic Syndrome Less << Not Applicable Completed - United States, Illinois ... More >> Northwestern University preventive Cardiology Center Chicago, Illinois, United States, 60611 Less <<
NCT00843661 HIV Hyperlipi... More >>demia HIV Infections Less << Phase 4 Unknown July 2012 Italy ... More >> Ospedale di Circolo and Fondazione Macchi Recruiting Varese, Italy, 21100 Contact: Anna Maria Grandi, MD    +390332278403    amgrandi@libero.it Less <<
NCT01010516 Dyslipidemia Phase 4 Unknown - Greece ... More >> University of Ioannina Medical School Recruiting Ioannina, Greece, 45 110 Contact: M S Elisaf, MD    +302651007509    egepi@cc.uoi.gr    Principal Investigator: Moses S Elisaf, MD          Sub-Investigator: Evangelos N Liberopoulos, MD          Sub-Investigator: Anastazia Kei, MD Less <<
NCT00362206 Hyperlipidemia Phase 3 Completed - -
NCT00491400 - Terminated(Insufficient enroll... More >>ment) Less << - -
NCT00400231 Metabolic Syndrome x Phase 2 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00632840 Obesity Lipid... More >> Disorders Hypertriglyceridemia Cardiovascular Disease Less << Phase 4 Completed - -
NCT00362934 Hyperlipidemia Phase 3 Completed - -
NCT00352183 Cardiovascular Diseases Phase 3 Completed - -
NCT01353404 Hyperlipidemia Phase 1 Completed - Korea, Republic of ... More >> Clinical Research Institute, Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT00349375 Hyperlipidemia Phase 3 Completed - -
NCT00965315 - - - -
NCT00299884 - Completed - Canada, Ontario ... More >> Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital Kingston, Ontario, Canada, K7L 5G2 Less <<
NCT00349284 Hyperlipidemia Combined Phase 3 Completed - Belgium ... More >> Site 113 Charleroi, Belgium Site 112 Couillet, Belgium Site 115 Dessel, Belgium Site 114 Dour, Belgium Site 106 Genk, Belgium Site 102 Genly, Belgium Site 111 Komen, Belgium Site 109 Kortessem, Belgium Site 104 Kortrijk, Belgium Site 108 Luik, Belgium Site 107 Menen, Belgium Site 105 Moen, Belgium Site 101 Oosteeklo, Belgium Site 110 Oostham, Belgium Site 116 Seraing, Belgium Site 103 Turnhout, Belgium France Site 213 Bondy, France Site 211 Le Beausset, France Site 209 Nantes, France Site 202 Orvault, France Site 212 Paris Cedex, France Site 206 Paris, France Site 208 Paris, France Site 203 Saint Cyr, France Site 210 Six Fours les Plages, France Site 201 St Sébastian sur Loire, France Site 205 St Sébastian sur Loire, France Site 207 St Sébastian sur Loire, France Site 204 Toulon, France Germany Site 313 Borna, Germany Site 307 Bretten, Germany Site 306 Dresden, Germany Site 305 Erbach, Germany Site 304 Frankfurt, Germany Site 308 Frankfurt, Germany Site 311 Frankfurt, Germany Site 301 Ilvesheim, Germany Site 302 Leipzig, Germany Site 303 Leipzig, Germany Site 314 Mannheim, Germany Site 309 Offenbach, Germany Site 312 Offenbach, Germany Site 310 Rodgau, Germany Less <<
NCT00732485 Burn Phase 2 Phase 3 Withdrawn(Principal Investigat... More >>or Changed) Less << December 2013 -
NCT00884819 Polycystic Ovary Syndrome Not Applicable Terminated(Poor recruitment) - Canada, Ontario ... More >> St. Joseph's Health Care London, Ontario, Canada, N6A 4L6 Less <<
NCT01141296 Primary Biliary Cirrhosis Phase 2 Withdrawn(Lack of funding) - United States, Florida ... More >> University of Miami Miami, Florida, United States, 33136 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55902 Less <<
NCT02166593 Combined Dyslipidemia Phase 3 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less <<
NCT00673881 - Completed - -
NCT02306902 Healthy Not Applicable Completed - -
NCT01048502 Cardiovascular Disease Not Applicable Completed - United States, Pennsylvania ... More >> Clinical and Translational Research Center (CTRC); Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01048502 - Completed - -
NCT00644592 - Terminated(supply issues with ... More >>the formulation of fenofibrate that was used.) Less << - -
NCT03615534 Atherogenic Dyslipidemia ... More >> Obesity Associated Disorder Less << Phase 4 Completed - Iraq ... More >> Al Kindy College of Medicine, University of Baghdad Baghdad, Iraq, 10045 Lewai S Abdulaziz Baghdad, Iraq, 10045 Less <<
NCT02823366 Primary Biliary Cirrhosis Phase 3 Unknown - China, Shaanxi ... More >> Xijing Hosipital Recruiting Xi`an, Shaanxi, China, 710032 Contact: Ying Han, Ph.D    86-29-84771539    hanying@fmmu.edu.cn    Contact: Yongquan Shi, Ph.D    86-29-84771515    shiyquan@fmmu.edu.cn Less <<
NCT03618797 Complex-dyslipidemia Phase 3 Completed - -
NCT03615534 - Completed - -
NCT00491400 Diabetes Mellitus ... More >> Metabolic Syndrome Less << Not Applicable Terminated(Insufficient enroll... More >>ment) Less << - United States, Massachusetts ... More >> Boston Medical Center Boston, Massachusetts, United States, 02118 Less <<
NCT00644592 Healthy Not Applicable Terminated(supply issues with ... More >>the formulation of fenofibrate that was used.) Less << - United States, Florida ... More >> University of Florida College of Pharmacy, Center for Pharmacogenomics Gainesville, Florida, United States, 32610 Less <<
NCT00891293 - Completed - -
NCT01956201 Mixed Hyperlipidemia Phase 3 Unknown August 2016 Korea, Republic of ... More >> Inje University Busan Paik Hospital Recruiting Busan, Korea, Republic of Contact: DaeKyung Kim          Pusan National University Hospital Recruiting Busan, Korea, Republic of Contact: Sangsu Kim          Kangwon University Hospital Recruiting Chuncheon, Korea, Republic of Contact: Yonghoon Kim          Daegu Catholic University Medical Center Recruiting Daegu, Korea, Republic of Contact: Hosang Son          Keimyung University Dongsan Medical Center Recruiting Daegu, Korea, Republic of Contact: HoChan Cho          Konyang University Hospital Recruiting Daejeon, Korea, Republic of Contact: Jangho Bae          Chonnam National University Hospital Recruiting Gwangju, Korea, Republic of Contact: YoungKun Ahn          Dongguk University Ilsan Hospital Recruiting Ilsan, Korea, Republic of Contact: KyungAh Kim          Inje University Ilsan Paik Hospital Recruiting Ilsan, Korea, Republic of Contact: SungYoon Lee          Chonbuk National University Hospital Recruiting Jeonju, Korea, Republic of Contact: Jaegun Chae          Hanyang University Guri Hospital Recruiting Kyunggi, Korea, Republic of Contact: Changmum Lee          Seoul National University Hospital, Bundang Recruiting Seongnam, Korea, Republic of Contact: Soo Lim          Asan Medical Center Recruiting Seoul, Korea, Republic of Contact: Kihoon Han          Eulji General Hospital Recruiting Seoul, Korea, Republic of Contact: KyungAh Han          Gangnam Severance Hospital Recruiting Seoul, Korea, Republic of Contact: Youngwon Yoon          Kangbuk Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: KiChul Sung          Kangdong Sacred Heart Hospital Recruiting Seoul, Korea, Republic of Contact: Duman Kim          Korea University Anam Hospital Recruiting Seoul, Korea, Republic of Contact: Singon Kim          Korea University Huro Hospital Recruiting Seoul, Korea, Republic of Contact: KyungMuk Choi          Kyunghee University Hospital at Gangdong Recruiting Seoul, Korea, Republic of Contact: Kyujung Ahn          Kyunghee University Medical center Recruiting Seoul, Korea, Republic of Contact: Woosik Kim          Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: MoonKyu Lee, M.D., Ph.D.          Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: HyeSeung Jung          Severance Hospital Recruiting Seoul, Korea, Republic of Contact: Sanghak Lee          SMG-SNU Boramae Medical Center Recruiting Seoul, Korea, Republic of Contact: SangHyun Kim          The Catholic University of Korea, St. Mary's Hospital Recruiting Seoul, Korea, Republic of Contact: SangHong Baik          The Catholic University of Korea, Uijeongbu St. Mary's Hospital Recruiting Seoul, Korea, Republic of Contact: HyunSik Son          The Catholic University of korea, Yeouido St. Mary's Hospital Recruiting Seoul, Korea, Republic of Contact: HyukSang Kwon          Ajou University hospital Recruiting Suwon, Korea, Republic of Contact: DaeJung Kim          Wonju Severance Christian Hospital Recruiting Wonju, Korea, Republic of Contact: Byungsoo Yoo Less <<
NCT02015988 Acute Coronary Syndrome ... More >> Diabetes Mellitus, Type 2 Hypertriglyceridemia Less << Phase 4 Unknown May 2017 Ukraine ... More >> State Institution "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine" Dnipropetrovsk, Ukraine Less <<
NCT00775827 Healthy Not Applicable Completed - India ... More >> Ranbaxy Research Laboratories Gurgaon, Haryana, India Less <<
NCT01320345 Type 1 Diabetes Mellitus ... More >> Retinopathy Diabetic Nephropathy Less << Phase 3 Unknown September 2014 United States, Oklahoma ... More >> Oklahoma University Health Sciences Center Not yet recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Alicia Jenkins, Professor       alicia-jenkins@ouhsc.edu    Principal Investigator: Alicia Jenkins, Professor          Principal Investigator: Timothy Lyons, Dr          Australia, New South Wales NHMRC Clinical Trials Centre Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Anthony Keech, Professor       tony@ctc.usyd.edu.au    Principal Investigator: Anthony Keech, Professor          Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Stephen Twigg, Professor       stephen.twigg@sydney.edu.au    Principal Investigator: Stephen Twigg, Professor          Westmead Children's Hospital Not yet recruiting Westmead, New South Wales, Australia, 2145 Contact: Kim Donaghue, Professor       kimd@chw.edu.au    Principal Investigator: Kim Donaghue, Professor          Australia, Victoria Royal Melbourne Hospital Not yet recruiting Melbourne, Victoria, Australia, 3050 Contact: Peter Colman, Professor       peter.colman@mh.org.au    Principal Investigator: Peter Colman, Professor          St Vincents Hospital Melbourne, Victoria, Australia, 3065 Less <<
NCT00816829 Dyslipidemia ... More >>Sleep Apnea Syndrome Overweight Obesity Less << Phase 2 Terminated(The study was prema... More >>turely terminated because of slow recruitment) Less << - France ... More >> Site 1 Paris, France Less <<
NCT02306889 Healthy Not Applicable Completed - -
NCT01109758 Healthy PHASE1 COMPLETED 2025-08-08 Site 1, London, United Kingdom
NCT00891293 Hypertriglyceridemia Phase 4 Completed - -
NCT03515213 Huntington Disease Phase 2 Recruiting December 31, 2019 United States, California ... More >> University of California, Irvine Recruiting Irvine, California, United States, 92697 Contact: Everlyne Gomez    949-824-8116    everlyng@uci.edu    Principal Investigator: Neal Hermanowicz, MD Less <<
NCT00775359 Healthy Not Applicable Completed - United States, Arizona ... More >> MDS Pharma Services Phoenix, Arizona, United States, 85044 Less <<
NCT00819910 - Terminated(Slow recruitment an... More >>d increase in deployment overseas limiting follow up) Less << - -
NCT00819910 Hypertriglyceridemia in Type 4... More >> Hyperlipidemia Non Diabetic Subjects With Normoglycemia Less << Phase 4 Terminated(Slow recruitment an... More >>d increase in deployment overseas limiting follow up) Less << - United States, Texas ... More >> Brooke Army Medical Center San Antonio, Texas, United States, 78234 Less <<
NCT02354976 Non-alcoholic Fatty Liver Dise... More >>ase (NAFLD Hypertriglyceridemia Less << Phase 2 Completed - Sweden ... More >> Research Site Göteborg, Sweden, 413 45 Research Site Malmö, Sweden, 205 02 Research Site Stockholm, Sweden, 11324 Research Site Uppsala, Sweden, 75237 Less <<
NCT01574131 Second or Third Degree Burns Phase 4 Terminated(lost funding) - United States, Texas ... More >> University of Texas Medical Branch Galveston, Texas, United States, 77551 Less <<
NCT00552747 Coronary Heart Disease ... More >> Hyperlipidemia Less << Phase 4 Completed - Mexico ... More >> Endocrinology Department National Institute of Cardiology Ignacio Chavez Mexico City, Mexico, 14080 Less <<
NCT00613613 Dyslipidemia Phase 4 Completed - United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT00816829 - Terminated(The study was prema... More >>turely terminated because of slow recruitment) Less << - -
NCT00813527 Hyperlipidemias Phase 2 Completed - -
NCT01142323 Primary Sclerosing Cholangitis Phase 1 Phase 2 Terminated - United States, Florida ... More >> University of Florida Gainesville, Florida, United States, 32608 University of Miami Miami, Florida, United States, 33136 Less <<
NCT02452255 Burn Phase 2 Phase 3 Recruiting December 2022 United States, Texas ... More >> Shriners Hospitals for Children Recruiting Galveston, Texas, United States, 77551 Contact: Cathy Reed, BSN    409-770-6987    ca2reed@utmb.edu    Contact: Deb Benjamin, MSN    409-770-6731    dbenjami@utmb.edu    Principal Investigator: David N Herndon, MD Less <<
NCT02262143 Mixed Dyslipidemias Phase 3 Completed - Korea, Republic of ... More >> Ildong Pharm. Seoul, Korea, Republic of Less <<
NCT01142323 - Terminated - -
NCT00928694 Dyslipidemia Phase 1 Completed - -
NCT00459745 Combined Hyperlipidemia Phase 3 Completed - -
NCT00928694 - Completed - -
NCT01280604 - Completed - -
NCT01280604 Hyperlipidemias Not Applicable Completed - United States, Georgia ... More >> Kaiser Permanente of Georgia Atlanta, Georgia, United States, 30305 Less <<
NCT00960687 Healthy Phase 1 Completed - -
NCT00246636 Hypertriglyceridemia Phase 4 Completed - -
NCT00575042 Primary Biliary Cirrhosis Phase 2 Completed - United States, Florida ... More >> University of Florida Gainesville, Florida, United States, 32610 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00961116 - Completed - -
NCT02354976 - Completed - -
NCT00960687 - Completed - -
NCT00961116 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. - Cetero Research Fargo, North Dakota, United States, 58104 Less <<
NCT02823353 Primary Biliary Cirrhosis Phase 3 Unknown July 2018 China, Shaanxi ... More >> Xijing Hosipital Recruiting Xi`an, Shaanxi, China, 710032 Contact: Ying Han, MD,PH.D    8602984771539    hanying@fmmu.edu.cn Less <<
NCT00872599 Hypertension Phase 4 Completed - United States, Tennessee ... More >> Vanderbilt University Nashville, Tennessee, United States, 37232 Less <<
NCT01023750 Hypertriglyceridemia|Insulin R... More >>esistance Less << COMPLETED 2025-07-12 UAB Kirklin Clinic, Birmingham... More >>, Alabama, 35294, United States Less <<
NCT00575042 - Completed - -
NCT00872599 - Completed - -
NCT01462877 Dyslipidemias ... More >> Cardiovascular Diseases Hypertriglyceridemia Less << Phase 4 Completed - China ... More >> Site Reference ID/Investigator# 64695 Xiamen, China, 36100 Less <<
NCT02153879 Type 2 Diabetes Mellitus ... More >> Dyslipidemia Less << Phase 4 Completed - Spain ... More >> Hospital Universitari Sant Joan Reus, Tarragona, Spain, 43204 Less <<
NCT01927315 Diabetes Diab... More >>etic Retinopathy Less << Phase 4 Unknown December 2015 Italy ... More >> University Hospital of Padova, Diabetes Outpatient Clinic Recruiting Padova, Italy, 35100 Contact: Gian Paolo Fadini, MD PhD    0039 049 8214318    gianpaolo.fadini@unipd.it    Principal Investigator: Gian Paolo Fadini, MD PhD          Sub-Investigator: Alberto Zambon, MD PhD Less <<
NCT01878227 Hyperlipoproteinemia Phase 3 Completed - China, Zhejiang ... More >> 1st Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310003 Less <<
NCT02232360 Coronary Artery Disease Phase 3 Unknown December 2018 Korea, Republic of ... More >> Konyang University Hospital Not yet recruiting Daejeon, Korea, Republic of Contact: Jang Ho Bae, MD          Principal Investigator: Jang Ho Bae, MD          Chonnam National University Medical School and Hospital Recruiting Gwangju, Korea, Republic of Contact: Young-Joon Hong, MD          Principal Investigator: Young-Joon Hong, MD          Inje University ilsanPaik Hospital Recruiting Ilsan, Korea, Republic of Contact: Sung Yoon Lee, MD          Principal Investigator: Sung Yoon Lee, MD          Gachon University Gil Medical Center Recruiting Incheon, Korea, Republic of, 405-760 Contact: Seung Hwan Han, MD, PhD    82-32-460-3054    shhan@gilhospital.com    Principal Investigator: Seung Hwan Han, MD          Chung-Ang University Hospital Recruiting Seoul, Korea, Republic of Contact: Sang-Wook Kim, MD          Principal Investigator: Sang-Wook Kim, MD          Seoul National Univesity Boramae Medical Center Not yet recruiting Seoul, Korea, Republic of Contact: Sang Hyun Kim, MD          Principal Investigator: Sang Hyun Kim, MD Less <<
NCT02965911 Primary Biliary Cirrhosis Phase 1 Phase 2 Recruiting January 2019 China ... More >> Beijing 302 hospital Recruiting Beijing, China, 100039 Contact: Zhengsheng Zou, Dr.          Principal Investigator: Zhengsheng Zou, Dr. Less <<
NCT03557983 Radiodermatitis Not Applicable Not yet recruiting April 13, 2020 China, Jiangsu ... More >> 苏州大学 Not yet recruiting Suzhou, Jiangsu, China, 215123 Contact: Shuyu Zhang, A/Prof.    86+15851417273    zhang.shuyu@hotmail.com Less <<
NCT02455336 Spinal Cord Injury ... More >> Dyslipidemia Less << Phase 2 Phase 3 Completed - United States, New Jersey ... More >> Kessler Institute for Rehabilitation West Orange, New Jersey, United States, 07052 United States, New York James J. Peters VA Medical Center, Bronx, NY Bronx, New York, United States, 10468 Less <<
NCT02314533 Microalbuminuria Phase 4 Unknown December 2016 -
NCT01965834 Multiple Myeloma PHASE2 TERMINATED 2016-07-01 University of Miami, Miami, Fl... More >>orida, 33136, United States Less <<
NCT02886299 Fenofibrate/Simvastatin Compar... More >>ison Less << Phase 4 Completed - -
NCT01965834 Multiple Myeloma PHASE2 TERMINATED 2016-07-01 University of Miami, Miami, Fl... More >>orida, 33136, United States Less <<
NCT01462877 - Completed - -
NCT02751710 Stage III Breast Cancer (T0N2,... More >> T1N2, T2N2, T3N1, 2 or T4) Stage IIb Breast Cancer (T3N0) Less << Not Applicable Recruiting December 2023 Canada, Ontario ... More >> Juravinski Cancer Centre Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Juliet Woll, BHSc    905-387-9711    wollj@HHSC.CA    Principal Investigator: Bindi Dhesy, MD          London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 4L6 Contact: Becky Petrie    519-685-8618    rebecca.petrie@lhsc.on.ca    Principal Investigator: Phillip Blanchette, MD          Ottawa Hospital Regional Cancer Centre Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Luisa Ianni    613-798-5555    luianni@toh.ca    Principal Investigator: Angele Arnaout, MD          Thunder Bay Regional Health Sciences Centre Recruiting Thunder Bay, Ontario, Canada, P7B 6V4 Contact: Lisa Miedema, RN       miedemal@tbh.net    Principal Investigator: Adrien Chan, MD          Sunnybrook Odette Cancer Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Debra Burns       debra.burns@sunnybrook.ca    Principal Investigator: Andrea Eisen, MD          Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Rehab Chahin    416-946-4501    Rehab.Chahin@uhn.ca    Principal Investigator: Tulin Cil, MD Less <<
NCT02246829 Neovascular Age-related Macula... More >>r Degeneration of All Subtypes Less << Phase 4 Completed - France ... More >> Service d'ophtalmologie Hôpital Henri Mondor 40, avenue de Verdun Creteil, France, 94000 Service Ophtalmologie CHU DIJON 14 rue Gaffarel BP 77908 Dijon, France, 21079 Service d'Ophtalmologie Hôpital de la croix rousse Lyon, France, 69317 Cabinet d'ophtalmologie 1 rue Pougin de la Maisonneuve Montargis, France, 45200 Sce Ophtalmologie CHU Nantes 1 place Alexis Ricordeau Nantes, France, 44093 Centre ophtalmique d'imagerie et de laser (CIL) 11 rue Antoine Bourdelle Paris, France, 75011 Sce du Pr SAHEL Fondation ROTHSCHILD 25 rue Manin Paris, France, 75019 Sce Ophtalmologie Hôpital Lariboisière 2 rue Ambroise Paré Paris, France, 75475 Service Opthalmo 2 Clinique Mathilde 4 rue de Lessard Rouen, France, 76100 Centre Ophtalmologie Transparence 30 Boulevard Heurteloup Tours, France, 37000 Less <<
NCT03407196 - Completed - Turkey ... More >> Keçiören Training and Research Hospital Ankara, Turkey, 06280 Less <<
NCT02440529 Orthopaedic Decision Making Not Applicable Terminated(Research staff deci... More >>sion) Less << - United States, Missouri ... More >> Truman Medical Center Kansas City, Missouri, United States, 64108 Less <<
NCT02408809 Cigarette Smoking Not Applicable Completed - -
NCT06755151 Primary Biliary Cholangitis (P... More >>BC) Less << PHASE3 RECRUITING 1935-12-01 Xijing hospital, Xi'an, Shaanx... More >>i, China Less <<
NCT03869931 Diabetes Mellitus|Diabetic Nep... More >>hropathies Less << PHASE3 UNKNOWN 2021-04-30 Singapore General Hospital, Si... More >>ngapore, 169856, Singapore Less <<
NCT03829514 Diabetes Mellitus, Type II PHASE4 COMPLETED 2020-03-04 Medical University of South Ca... More >>rolina, Charleston, South Carolina, 29425, United States Less <<
NCT05883865 Severe Hypertriglyceridemia Du... More >>ring Pregnancy Less << RECRUITING 2025-12-01 Hangzhou First People's Hospit... More >>al, Hangzhou, Zhejiang, 310000, China Less <<
NCT03874260 Dyslipidemias PHASE4 UNKNOWN 2020-03-31 Hallym University Dongtan Sacr... More >>ed Heart Hospital, Hwaseong-si, Korea, Republic of Less <<
NCT00483210 Tissue Lipid Metabolism WITHDRAWN - -
NCT05514119 Liver Transplant PHASE2 RECRUITING 2025-12-24 Mayo Clinic Arizona, Phoenix, ... More >>Arizona, 85254, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.77mL

0.55mL

0.28mL

13.86mL

2.77mL

1.39mL

27.71mL

5.54mL

2.77mL

References

 

Historical Records

Categories